Halofuginone, a specific inhibitor of type I collagen synthesis, attenuates osteoarthritis by inhibition of TGF-β activity and type H vessels in subchondral bone (Cui et al., 2016). The gene discussed is TGFB1; the disease is osteoarthritis.